FCGR3A and diffuse large B-cell lymphoma: An improved binding affinity to FcγRIIIa and potentiation of NK cell-mediated ADCC was as well achieved by the introduction of S239D and I332E amino acid substitutions to generate anti-CD19 mAb–tafasitamab (MOR208) [76], which was highly effective in the treatment of r/r DLBCL and r/r FL patients [77].